Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year
Ongoing Phase II Study Could Support Accelerated Approval
Executive Summary
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.
Merck Joins KRAS Stampede In Deal With Otsuka Affiliates
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports